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Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally
administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by
treatment with misoprostol (0.4–0.8 mg per d), both for 6 wk. The patients (n¼ 21) and a study nurse who
administered the trial were blinded. The endpoints were change in pain and need for cooling and global assess-
ment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and
change in pain were also recorded before and after each treatment period. Results were compared with data from
healthy control subjects (n¼ 11) that did not undergo treatment. Clinical safety and tolerability evaluation included
physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures
were signiﬁcantly better after treatment with misoprostol (po0.01) as compared with placebo treatment and after a
3- mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was
similar to the control group and signiﬁcantly lower when compared with baseline (po0.01) and placebo treatment
(po0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with
erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneﬁcial effect
of misoprostol is reduced microvascular arteriovenous shunting in affected skin.
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Erythromelalgia (EM) is a rare condition characterized by
red, hot, and painful extremities. Local skin cooling provides
relief. Warmth, exercise, dependency of the extremity, and
tight shoes and gloves intensify the discomfort (Thompson
et al, 1979). The condition may be primary or secondary to
another disease (Smith and Allen, 1938).
Numerous therapies have been used with varied suc-
cess, but no firm conclusions of the treatment effects can
be drawn from the published literature (Cohen, 2000; Davis
and Rooke, 2002; Mrk and Kvernebo, 2002). Management
of the patients includes information about support groups,
teaching non-harmful cooling techniques, and avoidance of
precipitating or exacerbating factors (exercise, increased
ambient heat). Underlying disease (secondary EM) or com-
plications to EM (edema, maceration, dermatitis) should be
corrected.
The pathogenesis of EM has been debated. Over the
most recent years, evidence for microvascular arteriove-
nous (AV) shunting in affected skin as the common final path
for the development of symptoms has been growing
(Kvernebo, 1998; Mrk et al, 2000; 2002a). The hypothesis
postulates that available blood is maldistributed in the skin.
An insufficient proportion of blood is directed through
nutritional capillaries, leading to skin hypoxia, while a large
proportion of the blood is shunted through microvascular
anatomical or functional AV anastomoses. The skin hypoxia
induces arteriolar dilatation resulting in increased, but still
maldistributed, skin perfusion, which gives rise to in elevated
skin temperature, accelerated metabolism, and a further
deterioration of skin nutrition. A vicious cycle is created
(Kvernebo, 1998). This common final path of the pathogen-
esis is probably triggered by a number of mechanisms
related to hemorheological problems, defects in prosta-
glandin metabolism, or sympathetic or endothelial function
(Jrgensen and Sndegaard, 1978; Drenth et al, 1996; van
Genderen et al, 1996; Littleford et al, 1999a, b; Sandroni
et al, 1999; Davis and Sandroni, 2002; Mrk et al, 2002b).
According to the shunt hypothesis, substances that alter
skin blood flow distribution or improve hemorheological
properties of the blood may improve skin oxygenation and
induce relief. The beneficial effects of vasodilators like
sodium nitroprusside have been reported (O¨zsoylu and
Coskun, 1984). Aspirin, which inhibits thrombocyte aggre-
gation, may promptly relieve EM symptoms secondary to
blood dyscrasia. Parenteral prostaglandin E1 (PGE1),
prostacyclins, or analogs have been described to have bene-
ficial effects (Belch, 1992; Kvernebo, 1998). In a recently
published pilot study, using infusion with the prostacyclin
analog iloprost, we have for the first time in a double-blind,Abbreviations: AV, arteriovenous; EM, erythromelalgia
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randomized study described reduced symptoms and
sympathetic dysfunction in EM patients (Kalgaard et al,
2003).
The present clinical trial was designed to determine
whether treatment with misoprostol, an oral PGE1 analog,
leads to improvement in EM symptoms as compared with
placebo treatment. The mean EM pain for 1 wk following
treatment was chosen as the primary clinical endpoint,
while the patients’ need for cooling and the global response
to the treatment were secondary variables. A physiological
study of the effect of misoprostol on the distribution of skin
perfusion was added to the clinical trial. In this study of
pathogenesis, we tested the hypothesis that misoprostol
redistributes skin perfusion in favor of nutritive perfusion in
patients with EM.
Results
All the enrolled patients received intended treatment, but
one was not available at the time of follow-up. The changes
in pain and cooling scores were calculated by subtracting
the scores of the last week of the actual period minus the
last week of the previous period. The change was sig-
nificantly better for both parameters during treatment with
misoprostol with compared with placebo (po0.01) and
follow-up (po0.01) (Fig 1). There was a correlation between
pain and cooling score values (r¼ 0.8, po0.01) when all
available pairs of data were used. Based on global self-
assessment, treatment with misoprostol was superior to
placebo (po0.01), but the improvement did not persist at
follow-up (Fig 1). No statistical difference was demonstrated
for global assessment between placebo and follow-up.
During study design, a reduction in pain score X20% was
considered to be clinically significant. Using this definition
of ‘‘success’’, 14 patients were responders on misoprostol,
compared with four on placebo and none in the follow-up
period (po0.05). Fourteen patients also reported improve-
ment in global assessment during misoprostol treatment
when compared with baseline, significantly better as com-
pared with placebo treatment (n¼5, po0.05).
Reported clinical adverse events are summarized in
Table I. All symptoms were within the known safety profile of
misoprostol or considered unrelated to the study medica-
tion. The reactions considered to be possible or probably
misoprostol-related were mild to moderate, dose-related,
and resolved after discontinuation of the study medication.
No clinically significant changes in laboratory test values or
vital signs were recorded during the course of the study.
After treatment with placebo, three patients returned
430% of the dispensed medication, and four after treat-
ment with misoprostol.
For the physiological part of the study, two patients did
not meet to the scheduled appointments after misoprostol
treatment, and when rescheduled the microscope was no
longer available. The number of asymptomatic patients after
heat provocation was significantly higher after misoprostol
(n¼ 16) as compared with baseline (n¼6, po0.05) and after
placebo treatment (n¼7, po0.05). The increase in pain
score after central body heating was significantly lower after
treatment with misoprostol as compared with baseline and
Figure1
Pain and cooling of affected skin were significantly reduced after
treatment with misoprostol as compared to placebo, and a
significant deterioration of pain was demonstrated after cessation
of misoprostol. Global assessment of EM suffering was signifi-
cantly improved after treatment with misoprostol as compared to
treatment with placebo. Distribution of change in pain score (visual
analogue scale, 0–100 mm), cooling score (Likert scale 0–8) and global
assessment (8-point scale) as compared to baseline during each study
period is presented as box plots, where the boxes show median with
quartiles and the error bars 10/90 percentiles. p¼0.01, po0.01.
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placebo (po0.01) (Fig 2). No statistical difference was
demonstrated between baseline and placebo.
On all occasions, patients and control subjects showed a
significant increase in LDPI-assessed perfusion after central
body warming (po0.01) (Table II). The pre-heating LDPI
values did not differ between the groups. After misoprostol
treatment, the increase in LDPI-assessed skin perfusion
following heating did not differ from the response in the
control group (Fig 3). This is in contrast to assessments at
baseline and after placebo treatment, where the increase in
skin perfusion was significantly larger (po0.01 and po0.05)
as compared with misoprostol and controls. Skin perfusion
was reduced in one patient after heat provocation. This
patient had an EM attack with high skin temperature and
high perfusion just prior to heat provocation. T
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Figure 2
Increase of pain score induced by heat provocation was sig-
nificantly reduced after misoprostol treatment as compared to
baseline and after treatment with placebo. Data are presented as
box plots, where the boxes show median with quartiles and 10/90-
percentiles. VAS¼ visual analogue scale, 0–100 mm. po0.01.
Table I. Adverse events
Placebo (n) Misoprostol (n)a
None 7 7
Gastrointestinal 8 12
Abdominal pain 0 7
3
Nausea 1 3
3
Loose stool/diarrhea 6 2
2
Vomiting 0 2
3
Flatulens 1 4
3
Sore throat 5 2
1
Headache 0 1
2
Insomnia 1 0
aRelationship to misoprostol: 1unlikely, 2possibly, 3probably.
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After central body warming, capillary density was
reduced in EM patients at baseline, after placebo and after
misoprostol treatment, in spite of the significant increase in
temperature and perfusion (Table II). This was in contrast to
findings in controls where capillary density was unchanged
in response to heat provocation. The average distance
between neighboring skin capillaries (mutual distance), an
estimate of diffusion distances for oxygen and nutrients,
increased in patients after warming, but not in controls. For
both CAVM parameters, treatment with misoprostol tended
to give results more similar to controls.
Retrospective subgroup analyses of demographic (age,
gender) and clinical characteristics (age of onset and
duration of EM, EM category, or baseline severity, respon-
ders versus non-responders) did not demonstrate signifi-
cant differences for any clinical or physiological variables.
Discussion
The oral PGE1 analog misoprostol reduced EM symptoms
significantly more than treatment with placebo, as deter-
mined by pain and cooling scores, and global assessment.
The therapeutic effect had ceased 3 mo after discontinua-
tion of misoprostol treatment. Furthermore, misoprostol
reduced pain and hyperemia, induced by central body
heating, as compared with patient recordings at baseline
and after placebo treatment. To our knowledge, this is the
first publication of a properly designed placebo-controlled
clinical trial for the treatment of EM.
The main cause of the lack of clinical trials in EM patients
is the low prevalence of the condition (Kvernebo, 1998). The
present study was possible due to our systematic building
up of a database of patients over a time period of 20 y. We
applied wide inclusion and limited the number of exclusion
criteria to obtain a sufficient number of patients. This
resulted in a relatively heterogeneous study population with
respect to severity and etiology, increasing the external
validity of the results. The patients were, with one excep-
tion, classified as chronic cases, shown to have a stable
course (Kalgaard et al, 1997). In this study rather small
fluctuations in symptoms were recorded during enrolment
and treatment with placebo. This stability is an important
requirement for choosing a crossover design. Long-term
remission (3 mo to 2 y) has previously been described after
PGE1 infusions (Kvernebo, 1998). The non-randomized study
design was chosen to eliminate a possible carry-over effect
of misoprostol from the first to the second treatment.
The outcome measures had previously been found to be
clinically relevant in the characterization of EM severity
(Kalgaard et al, 1997, 2003; Kvernebo, 1998). The VAS
method is the most commonly used tool to quantify pain
intensity, because it is easily administered, requires a mini-
mum of explanation to respondents, and is a sensitive tool
for the measurement of pain differences (Torrance et al,
2001). We reduced the effect of daily fluctuations in EM
severity by applying mean values of daily recordings for 1
wk. To ensure stable environmental conditions during the
study, the treatment period was in the wintertime with a
stable cold climate in Norway (the mean temperature with
monthly mean range in the treatment period was þ 0.11C
(1.31C–1.41C). The follow-up evaluation was in May with
mean temperature þ 11.61C.
The dosage of misoprostol treatment was based on
recommendations from the pharmaceutical company
(Searle), Norwegian Medicines Control Authority, and pre-
study beneficial experience from two patients with EM.
A dose–response curve for patients with EM was not
performed. The duration of the treatment period represents
a compromise between previous experience with miso-
prostol treatment in EM, and the potential of disease
instability and inadequate patient cooperation with a long-
lasting intervention. The incidence of drug-related side
effects was minimized by a stepwise dosage increase,
transient dose reduction if necessary, and administration of
the study medication immediately after meals. More fre-
quent adverse events during treatment with misoprostol
may potentially have biased the blinding of the study
medication and reduced adherence to therapy. Intolerance
to drug therapy did not cause any patient withdrawals
during the treatment period.
The treatment effect of misoprostol is statistically super-
ior to placebo. We consider this difference to be clinically
relevant because of the size of the effect, the large number
of responders, and the significant correlation between the
clinical outcome measures. At a 3-mo follow-up, no long-
term effect of misoprostol could be demonstrated.
No constant effect of any treatment apart from local
cooling has so far been documented. A limited number of
Figure 3
Increase in LDPI assessed skin perfusion induced by heat
provocation was significantly lower in the control group and in
EM patients after treatment with misoprostol as compared to
baseline and placebo. Data are presented as box plots, where
the boxes show median with quartiles and 10/90 percentiles.
AU¼arbitrary units. po0.05 as compared to control and misoprostol,
po0.01 as compared to control and misoprostol.
590 MØRK ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
patients is one explanation. The other is that EM patients
are a heterogeneous group with respect to disease mecha-
nisms. We have managed to collect a sufficient number of
patients to draw statistical conclusions, but the low number
makes retrospective subgroup analyses difficult. Those
patients reporting placebo effects reported further improve-
ment after treatment with misoprostol. One patient with
thrombocythemia had EM symptoms for the first time just
prior to the start of this study. Maximum EM severity was
reached within 1 mo of placebo treatment and the patient
was asymptomatic 1 wk prior to the stop of placebo. The
remission persisted to the end of this study, consistent with
acute EM. If patients with low adherence to treatment
(return of 430% of dispensed tablets) and/or the patient
with acute EM are eliminated, the clinical efficacy of
misoprostol is strengthened versus placebo.
In previous studies we have used LDPI and CAVM to
assess microvascular AV shunting as a pathogenetic
mechanism in EM (Mrk et al, 2000; 2002a). In the present
therapeutic trial, we have assessed the effect of treatment
using the same two techniques. The LDPI signal is
dependent on capillary nutritive perfusion as well as blood
flow in venous plexa and through AV shunts, global skin
perfusion (Arildsson et al, 2000; Nilsson et al, 2003). The
laser Doppler signal is influenced by skin thickness and
color. In this study all patients were Caucasians and the
measurements were performed at the same site. In a
previous publication, we demonstrated that the flow
increase in the feet of symptomatic EM patients following
central body warming was higher as compared with
asymptomatic patients and controls (Mrk et al, 2000). It
was postulated that the cause was a disproportional
increase in thermoregulatory skin perfusion through micro-
vascular AV shunts. The EM patients in this study also had a
significantly larger increase in global skin perfusion follow-
ing warming at baseline and after placebo treatment, as
compared with controls (Fig 4). After misoprostol treatment,
the EM patients experienced reduced pain after warming,
and at the same time the flow increase was reduced to
levels comparable to the control group. The simultaneous
reduction of heat-induced pain and reduced hyperemia may
imply reduced shunting as a mechanism of action for the
beneficial effect of misoprostol. When nutritional capillaries
are opened by the vasodilator, the EM symptoms are re-
duced or disappear due to improvement or elimination of
skin hypoxia. The clinical effect of treatment is dependent
on the capacity of the drug to redistribute the skin perfusion
in favor of the capillaries. With higher levels of skin oxygen
tension, the supplying arterioles constrict, with the con-
sequence that the total skin perfusion decreases. As the
global skin perfusion is maldistributed in favor of the shunt
flow, the arteriolar constriction reduces skin temperature,
skin metabolism and oxygen consumption, and the vicious
cycle is broken.
In a previous paper, EM patients who did not develop
symptoms during heat provocation behaved like controls in
respect to CAVM parameters. Patients who developed pain
during warming reduced the skin capillary density (Mrk
et al, 2002a). Also these findings gave support to the
microvascular AV hypothesis as a pathogenetic mechan-
ism. The EM population in the present study was a mixture
of patients with and without symptoms both before and
after heat provocation. At baseline, six of 21 patients were
asymptomatic after heat provocation, compared with 16 of
21 following misoprostol. In spite of the clinical effect and
the LDPI findings, we still found a reduction in CAVM-
assessed capillary density and an increase in mutual
distance induced by warming (Table II). Shunting therefore
still takes place after misoprostol treatment, but may be
below a critical level for inducing pain.
In conclusion, misoprostol treatment is statistically
superior to treatment with placebo, and we consider the
treatment difference to be clinically significant. The me-
chanism of the effect is probably reduction of microvascular
AV shunting. The oral administration of the treatment is also
of great value to the patients. The drug is relatively well
tolerated, and we therefore recommend misoprostol as the
first-line treatment of EM. In severe and resistant cases,
parenteral treatment with prostanoids may be indicated. In
future, larger randomized parallel group clinical trials are
desired to document long-term treatment effects, and the
study responses in subgroups of patients. Such studies will
have to be undertaken on a multicenter basis.
Materials and Methods
Subject selection Patients were recruited from our database of
106 EM cases systematically collected since 1983. Adult (ages 18–
75 y), primary or secondary EM cases, with mild to severe
symptoms (average cooling score X1 the week prior to inclusion,
see Methods) localized to the feet, were assessed for eligibility
(Kvernebo, 1998). Fertile females had a negative pregnancy test
before enrolment, and were instructed to practise contraception
during the study. Exclusion criteria included confounding con-
current diseases or drugs. Combining the current clinical and
epidemiological information in our database (Kalgaard et al, 1997),
63 patients were found suitable for a questionnaire about EM
symptoms for the last year. Twenty-one patients entered a
screening procedure 1 wk prior to intervention, including medical
history, physical examination, and laboratory evaluation, following
a daily recording of current disease severity according to the
cooling score (see Evaluation procedure). All patients enrolled in
the study underwent intervention after signing a written informed
consent form. For physiological evaluation of the effect of therapy,
the patients were compared with values from 11 healthy controls.
For logistic reasons, some control subjects were examined with
one of two measuring techniques. The baseline demographics and
clinical characteristics are given in Table III. Nine patients were
classified as secondary EM, and comorbidities included connec-
tive tissue disease (n¼ 3), myeloproliferative disease (n¼ 2),
diabetes mellitus (n¼ 2), and sciatica (n¼ 2). Nine patients had
previously used aspirin, of whom one with EM secondary to
polycythemia had a beneficial effect. They were instructed not to
use aspirin during the course of the study. The Regional Committee
of Research Ethics and the Norwegian Medicines Control Authority
approved the study protocol. The Declaration of Helsinki
Guidelines were followed.
Study design Based on an assumption on available patients,
power considerations and previous experience with a possible
carry-over effect of PGE1 in EM patients, we chose a double-blind,
placebo-controlled, non-randomized, one-way crossover design
(Fig 4). A study nurse, unaware of the treatment sequence,
administered and monitored the study medication and gave
patients oral and written information throughout the study. The
study nurse also instructed the patients in the scoring of out-
come measures, handled, collected, checked and registered the
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patients’ self-assessment forms, laboratory and adverse events
reports, concomitant therapy and other procedures, and recorded
vital signs (pulse and blood pressure). After a 1-wk run-in period,
placebo followed by misoprostol 0.2 mg tablets were given, both
for 6 wk. The placebo tablets were identical (size, form, and color)
to the misoprostol tablets. The patients were instructed to take one
tablet twice daily for the first week and, if tolerated, two tablets
twice daily for the next 5 wk. The tablets should be taken
immediately after a meal to reduce the chance of side effects.
A questionnaire was sent to the patients at 3-mo follow-up. The
control group was examined only once in the laboratory.
Evaluation procedure The primary clinical efficacy measure was
change in pain. The patients scored the pain intensity before and
after interventions from the most affected foot for the last week on
a 100 mm visual analog scale (VAS), where the anchors were
marked ‘‘no EM pain’’ (0 mm) and ‘‘worst imaginable EM pain’’ (100
mm) by placing a perpendicular line somewhere on the non-graded
line (Torrance et al, 2001). Secondary clinical outcome measures
included change in cooling score and patients’ global assessment
of response to treatment. The cooling score was rated daily on
an 8-point Likert (ordinal) scale during run-in and during each
treatment period. Score 1 implies feeling uncomfortably warm
without a need for cooling, and score 8 implies maximal burning
pain with a continuous need for cooling or plexus/epidural
anesthesia (Kalgaard et al, 1997). The scores are given as weekly
averages. The global assessment (8-point scale: þ 4¼ cured,
þ 3¼greatly improved, þ 2¼moderately improved, þ 1¼ slightly
improved, 0¼ no change, 1¼ slightly decreased, 2¼ moder-
ately decreased and 3¼greatly decreased) of EM symptoms as
compared with baseline was rated and at the end of weeks 6, 12,
and 24 (Fig 4). Safety monitoring included clinical evaluation and
adverse event reports (weeks 6, 12, and 24). Laboratory evaluation
(weeks 6 and 12) included hematology, liver and renal function
tests, glucose, electrolytes, and urine stix. The principal investi-
gator determined the potential relationship of the adverse events
to the study medication as unrelated, possible, probably, and
definitely. Compliance was assessed by the number of tablets
returned. On three occasions (Fig 1), pain score and physiological
skin perfusion parameters (skin temperature, laser doppler perfu-
sion imaging (LDPI), computer-assisted video microscopy (CAVM))
were recorded before and after provocation with central body
heating.
Methods Skin temperature was measured at the pulp of the first
left toe using a digital handheld thermometer (Anritsu HFT-80
Meter, Japan). The principles governing measurements of micro-
vascular perfusion by laser Doppler flowmetry have been de-
scribed in detail elsewhere (Nilsson et al, 2003). In our study the
skin microcirculation was examined with LDPI (PIM 1.0 Lisca
Development AB, Linko¨ping, Sweden), a technique employing
multiple point recording for visualization of skin blood perfusion in
terms of two-dimensional flow maps. LDPI offers a system for non-
invasive, non-touch imaging of superficial microvascular blood
perfusion and therefore prevents external mechanical sensory
stimuli that may influence perfusion in the microvascular network
under study. The complete system consists of a computer-
controlled laser scanner and software for flow visualization. In
microvascular applications the laser Doppler technique gives a
semi-quantitative estimate of the perfusion. Data are expressed as
flux or perfusion, defined as the product of the number and mean
velocity of the blood cells in the measuring volume. The LDPI
output is dependent on global skin perfusion, i.e., both nutritive
capillary and AV shunt flow. The technique has previously been
used to study shunt flow in EM patients (Mrk et al, 2000).
Combining modern microscopic techniques and information
technology, a package able to facilitate the extraction of capillary
parameters from microscopic skin images has been developed,
analyzing capillary density (Zhong et al, 2000). The software can
also calculate the mutual distance, which after creation of a
triangulation map between visible capillaries gives the average
length of the limbs of the triangles. The hardware of the
microscopy system comprises a video capillary microscope and
a PC with special software. The capillary microscope is a portable
video microscope with a video signal control unit and a hand-
held mini-CCD camera (Microvision MV2100, Finlay Microvision,
Warwickshire, UK). Magnification of the system was set to 200
to enable investigation of an ensemble of approximately 100
capillaries in a field of view of 1.7 mm2. The color images captured
by the system show capillary ensembles in which the capillaries
appear as dark red spots with comma-like shapes. These spots
are actually the apexes of the active capillary loops perpendicular
to the skin surface. Changes in capillary density and mutual
distance were used as parameters for nutritive perfusion. The
technique has previously been used to support the hypothesis of
AV shunting in EM (Mrk et al, 2002a).
Table III. Demographic and clinical data of patients with
erythromelalgia and healthy controls
EM
Control
CAVMa
Control
LDPIb
Agec 47.8
(21.2–60.6)
29.0
(24.3–75.2)
38.3
(24.3–75.2)
Female/male 14/7 4/7 9/2
Duration of EMc 11.2 (0.1–34.7)
EM severityc,d 2.7 (1.0–7.0)
No. of smokers 15 2 3
Cigarettes per d 15 (3–30) 10 (8–12) 10 (8–12)
aComputer-assisted video microscopy.
bLaser doppler perfusion imaging.
cValues given as median with total range.
dCooling score in the run-in period.
Figure 4
Study flow chart.
592 MØRK ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Laboratory procedures The subjects were instructed not to eat,
drink coffee, tea or alcohol, or smoke for a minimum of 3 h before
measurements. Twenty minutes prior to measurements, they were
recumbent in a room with an ambient temperature of 231C (221C–
24)1C without physical or psychological stress. In order to induce
EM attacks, the subjects were covered with multiple duvets,
except for the head, for 30 min. A metal cage separated the feet
from the duvets. Skin temperature, skin perfusion levels, and
current pain intensity (VAS) were recorded before and after central
body heating. If pain was rated 0–10 mm on the VAS scale, the
patients were considered asymptomatic. The measurement site for
capillary microscopy was the terminal phalanx of the first toe, just
proximal to the nail bed. In this region the capillary loops are
perpendicular to the skin surface and the vasculature contains
numerous AV shunts (Grant and Bland, 1931; Sherman, 1963). For
LDPI, the measurement site was in the anterior section of the foot
arch containing some, but fewer, AV shunts. Microscopic images
were recorded before and after central body heating at tiny spots
marked with black ink in the nail fold area. To make the skin more
transparent and to minimize reflections from the surface, the
measurement sites were prepared with immersion oil of room
temperature just prior to measurements. The handheld video-
microscopy unit was vertical to the skin surface and hardly
touching it so as to prevent application of pressure to the
underlying tissue. The intensity of the light source was adjusted
to maximize the visual contrast in the image. Captured images
were stored in the internal database of the image capillary analysis
program for later processing. The extent of the skin area to be
imaged by laser Doppler was marked on the skin, so that the same
area was scanned before and after heating. The distances of the
measured areas to anatomical landmarks were recorded, so that
the same area could be measured at baseline and after treatment
with placebo and misoprostol. The distance between the scanner
head and the skin was set to 10 cm in all measurements together
with an image format of 20  20 pixels, and resolution was set
to ‘‘high’’ giving a morphological resolution level of approximately
0.4 mm. The patients rested in a supine position, with the test
foot stabilized with pillows of sand to avoid gross movement
artifacts.
Statistical analyses It was calculated that a sample size of 20
patients would have 80% power to detect a difference ofX20% in
the primary efficacy variable at a 5% significance level. Values
showed a skewed distribution, as assessed graphically and by the
Kolmogorov–Smirnov test, and are given as medians with total
range or box plots with quartiles and 10-, 90-percentiles. Efficacy
and safety outcomes were analyzed using Friedman’s test for more
than two groups and the Wilcoxon signed ranks test for two
groups. Fisher’s, Kruskal—Wallis, and Mann–Whitney tests were
used comparing different groups. Analyses were applied on the
intention-to-treat population. If patients discontinued the study
prematurely, missing data were estimated by carrying data forward
from the previous visit. Differences were considered statistically
significant if p values were p5%, after adjustments for multiple
comparisons. All significance levels reported are two-tailed.
Retrospective exploratory subgroup analyses were carried out
according to clinically relevant combinations of baseline data,
using Fisher’s, Mann—Whitney, and Spearman ranks correlation
tests. Analyses were performed using SPSS 10.0 (SPSS, Chicago,
Illinois) and nQuery Advisor 2.0 (Statistical Solutions, Cork, Ireland)
software.
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